Kennedy Capital Management Inc. acquired a new stake in shares of Inogen, Inc (NASDAQ:INGN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 43,196 shares of the medical technology company’s stock, valued at approximately $4,122,000. Kennedy Capital Management Inc. owned 0.21% of Inogen at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Inogen by 145,976.1% in the first quarter. BlackRock Inc. now owns 2,110,800 shares of the medical technology company’s stock worth $163,711,000 after acquiring an additional 2,109,355 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Inogen by 4.8% in the first quarter. Vanguard Group Inc. now owns 1,213,605 shares of the medical technology company’s stock worth $94,127,000 after acquiring an additional 55,802 shares during the period. Blair William & Co. IL boosted its holdings in shares of Inogen by 1.9% in the first quarter. Blair William & Co. IL now owns 921,693 shares of the medical technology company’s stock worth $63,462,000 after acquiring an additional 17,377 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Inogen by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 502,412 shares of the medical technology company’s stock worth $38,967,000 after acquiring an additional 3,796 shares during the period. Finally, State Street Corp boosted its holdings in shares of Inogen by 8.0% in the first quarter. State Street Corp now owns 398,412 shares of the medical technology company’s stock worth $30,901,000 after acquiring an additional 29,649 shares during the period.
TRADEMARK VIOLATION WARNING: This story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2017/09/17/kennedy-capital-management-inc-acquires-new-holdings-in-inogen-inc-ingn.html.
In related news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total value of $1,283,380.00. Following the completion of the transaction, the director now owns 7,808 shares of the company’s stock, valued at approximately $715,759.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Heath Lukatch sold 2,500 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $97.44, for a total transaction of $243,600.00. Following the completion of the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $243,600. The disclosure for this sale can be found here. Insiders sold a total of 44,667 shares of company stock valued at $4,170,776 in the last ninety days. 5.31% of the stock is currently owned by insiders.
Inogen, Inc (INGN) opened at 100.87 on Friday. The stock has a 50 day moving average price of $95.95 and a 200-day moving average price of $87.38. Inogen, Inc has a 12-month low of $50.24 and a 12-month high of $105.35. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of 87.56 and a beta of 1.02.
Inogen (NASDAQ:INGN) last issued its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.10. The company had revenue of $64.10 million during the quarter, compared to the consensus estimate of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. Inogen’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.25 EPS. Equities analysts predict that Inogen, Inc will post $1.21 EPS for the current fiscal year.
A number of research firms have recently commented on INGN. BidaskClub lowered Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $90.00 price target on shares of Inogen in a report on Tuesday, September 12th. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $108.00 price target on shares of Inogen in a report on Friday, September 1st. Finally, J P Morgan Chase & Co raised their price target on Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $91.33.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.